EUVIMEDEUVIMED entdecken
Multizentrische Studie

Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom

Samuel Hsiang Lim iD, Beatriz Gros, Esha Sharma, Anouk Lehmann, James O Lindsay, Louise Caulfield, Daniel R Gaya, Jo Taylor, Jimmy Limdi, Jon Kwok, Elinor Shuttleworth, Anjan Dhar und 12 weitere

Inflammatory Bowel Diseases · 01.08.2024 · 30 (8) · 1284-1294

DOI: 10.1093/ibd/izad166 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Inflammatory Bowel Diseases, online erschienen am 21.08.2023. Verfasst von Samuel Hsiang Lim und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Gastrointestinal Agents, Quality of Life. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Medical Research Council.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aims Despite intravenous (IV) vedolizumab being established for treatment of inflammatory bowel disease (IBD), the novel subcutaneous (SC) route of administration may provide numerous incentives to switch. However, large-scale real-world data regarding the long-term safety and effectiveness of this strategy are lacking.

Methods

IBD patients on IV vedolizumab across 11 UK sites agreed to transition to SC injections or otherwise continued IV treatment. Data regarding clinical disease activity (Simple Clinical Colitis Activity Index, partial Mayo score, and modified Harvey-Bradshaw Index), biochemical markers (C-reactive protein and calprotectin), quality of life (IBD control), adverse events, treatment persistence, and disease-related outcomes (namely corticosteroid use, IBD-related hospitalization, and IBD-related surgery) were retrospectively collected from prospectively maintained clinical records at baseline and weeks 8, 24, and 52.

Results

Data from 563 patients (187 [33.2%] Crohn’s disease, 376 [66.8%] ulcerative colitis; 410 [72.8%] SC, 153 [27.2%] IV) demonstrated no differences in disease activity, remission rates, and quality of life between the SC and IV groups at all time points. Drug persistence at week 52 was similar (81.1% vs 81.2%; P = .98), as were rates of treatment alteration due to either active disease (12.2% vs 8.9%; P = .38) or adverse events (3.3% vs 6.3%; P = .41). At week 52, there were equivalent rates of adverse events (9.8% vs 7.8%; P = .572) and disease-related outcomes. IBD control scores were equivalent in both IV-IV and IV-SC groups.

Conclusions

Switching to SC vedolizumab appears as effective, safe, and well tolerated as continued IV treatment and maintains comparable disease control and quality of life as IV treatment at 52 weeks.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedGastrointestinal AgentsQuality of LifeHumansFemaleMaleAdultUnited KingdomInjections, SubcutaneousRetrospective StudiesMiddle AgedColitis, UlcerativeTreatment OutcomeInflammatory Bowel DiseasesCrohn DiseaseRemission Induction

Stichwörter der Autor:innen

inflammatory bowel diseasesubcutaneousvedolizumab

Substanzen

vedolizumabAntibodies, Monoclonal, HumanizedGastrointestinal Agents

Autor:innen und Institutionen

  • Department of Gastroenterology, Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom.
  • Edinburgh IBD Unit, NHS Lothian, Edinburgh, United Kingdom.
  • Department of Gastroenterology, Royal London Hospital, Bart's Health NHS Trust, London, United Kingdom.
  • Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom.
  • Department of Gastroenterology, Northern Care Alliance NHS Foundation Trust, Greater Manchester, United Kingdom.
  • Department of Gastroenterology, Lancashire Teaching Hospitals NHS Foundation Trust, Preston, United Kingdom.

ORCID-Profile: Samuel Hsiang Lim, Peter Irving

Förderung

  • Medical Research Council

Zitieren

APA

Lim, S. H., Gros, B., Sharma, E., Lehmann, A., Lindsay, J. O., Caulfield, L., Gaya, D. R., Taylor, J., Limdi, J., Kwok, J., Shuttleworth, E., Dhar, A., Burdge, G., Selinger, C., Cococcia, S., Murray, C., Balendran, K., Raine, T., George, B., …, & Samaan, M. (2024). Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom. Inflammatory Bowel Diseases, 30(8), 1284-1294. https://doi.org/10.1093/ibd/izad166

Vancouver

Lim SH, Gros B, Sharma E, Lehmann A, Lindsay JO, Caulfield L, et al. Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom. Inflammatory Bowel Diseases. 2024;30(8):1284-1294. doi:10.1093/ibd/izad166

BibTeX
@article{Lim2024,
  author = {Lim, Samuel Hsiang and Gros, Beatriz and Sharma, Esha and Lehmann, Anouk and Lindsay, James O and Caulfield, Louise and Gaya, Daniel R and Taylor, Jo and Limdi, Jimmy and Kwok, Jon and Shuttleworth, Elinor and Dhar, Anjan and Burdge, Gemma and Selinger, Christian and Cococcia, Sara and Murray, Charles and Balendran, Karthiha and Raine, Tim and George, Becky and Walker, Gareth and Aldridge, Robin and Irving, Peter and Lees, Charlie W and Samaan, Mark},
  title = {Safety, Effectiveness, and Treatment Persistence of Subcutaneous Vedolizumab in IBD: A Multicenter Study From the United Kingdom},
  journal = {Inflammatory Bowel Diseases},
  year = {2024},
  volume = {30},
  number = {8},
  pages = {1284--1294},
  doi = {10.1093/ibd/izad166}
}
Kostenlos starten →